

1  
2 **Effects of mesenchymal stem cells and their derived microvesicles**  
3 **on pulmonary toxicity induced by petrol exhaust nanoparticle;**  
4 **Histological and Immuno-Histochemical Study**  
5  
6  
7  
8

9 **Abstract**

10  
11 **Background.** Diesel vehicles exhaust contain toxic nanoparticles that drastically  
12 affect lung tissue due to their direct cytotoxic effects, induction of oxidative stress,  
13 inflammatory signaling pathways and DNA damage. Mesenchymal stem cells  
14 (MSCs) exhibit anti-inflammatory effects and efficient regenerative capacity in  
15 chronic lung diseases.

16  
17 **Objectives.** Evaluation of the effects of MSCs and MSCs-derived micro vesicles  
18 (MSCs-MVs) on pulmonary toxicity induced by diesel exhaust nanoparticles  
19 (DENPs).

20  
21 **Materials and methods.** Sixty male rats were equally divided into: Group I (Control  
22 rats), Group II (DENPs group) received repeated doses of DENPs (180µg/rat)  
23 intratracheally every other day for 6 days, Group III (MSCs group) received MSCs  
24 intravenously ( $3 \times 10^6$  cells) after the last dose of DENPs and Group IV (MSCs-MVs  
25 group) received MSCs-MVs (0.5 mg/mL) intravenously after the last dose of DENPs.  
26 Lung tissue were subjected to histological and immunohistochemical assessment.  
27 Inflammatory cytokines and bronchoalveolar lavage fluid (BALF) content of  
28 inflammatory cells, albumin, LDH and total proteins were evaluated.

29  
30 **Results.** Histological picture of lung tissue in DENPs group showed numerous  
31 collapsed alveoli, thick interalveolar septa and marked cellular infiltration. Elastic  
32 fibers were markedly decreased by DENPs. increased optical density of NF-κB/p65  
33 immunoreactivity. BALF showed significant elevation of inflammatory cytokines  
34 (TNF-α, IL-6), polymorphonuclear leukocytes (PMN), neutrophils, macrophages,  
35 LDH, total proteins and albumin. Treatment with either MSCs or MSCs-MVs led to a  
36 significant amelioration of all of the aforementioned studied parameters.

37  
38 **Conclusion.** MSCs-MVs and MSCs showed significant therapeutic effects against  
39 DENPs damaging effects on the lung tissues via their regenerative capacity and anti-  
40 inflammatory effects.

41  
42 **Keywords;** Diesel exhaust nanoparticles; MSCs, pulmonary toxicity, microvesicles

43 **Introduction**

44 Diesel engine exhaust nanoparticles (DENPs) were classified by the World Health  
45 Organization as a group 1 carcinogen to humans (1). Epidemiological data showed  
46 that exposure to DENPs is associated with higher risk of morbidity and mortality

47 related to pulmonary and cardiovascular diseases, development and progression of  
48 atherosclerosis and lung cancer **(2)**. The Lung is the first target confronted by  
49 DENPs-mediated damage. The most prominent cellular responses are the induction  
50 of pulmonary oxidative stress and pro-inflammatory signaling cascade which are  
51 known to contribute to the onset of chronic respiratory diseases such as chronic  
52 obstructive pulmonary disease (COPD) and lung fibrosis. Fibrotic respiratory  
53 disorders develop as consequences of DENPs-induced oxidative stress, chronic  
54 inflammation, bronchial asthma and genotoxicity **(3,4)**.

55 Up to our best of knowledge there are no previous studies conducted on the use of  
56 stem cells in DENPs mediated pulmonary toxicity. However, Mesenchymal stem  
57 cells (MSCs) showed prominent anti-inflammatory and antioxidant effects in other  
58 chronic diseases such as rheumatoid arthritis **(5)**, atherosclerosis **(6)**, inflammatory  
59 bowled diseases **(7)** and inflammatory skin diseases **(8)**. MSCs mediate significant  
60 immunomodulatory effects by modulation of T and B cell proliferation and  
61 differentiation, dendritic cell growth and the activity of natural killer cells **(9)**. MSCs  
62 are polarized towards the anti-inflammatory directions in several auto-immune  
63 disorders with down-regulation of pro-inflammatory cytokines **(5)**.

64 Stem cells are endowed with major capacity of multilineage differentiation and self-  
65 renewal which allows them to be a significant contributor in tissue homeostasis.  
66 Moreover, stem cells have an efficient DNA repair machinery that protects them and  
67 the surrounding niche from genotoxic insults **(10-12)**. Diesel exhaust nanoparticles  
68 exhibit marked genotoxic potentials by their direct oxidative DNA damage with single  
69 strand breaks, and down-regulation of expression of genes involved in DNA damage  
70 repair **(13)**. Stem cells have the potentials to efficiently combat the genotoxicity  
71 induced by DENPs.

72 Cells release Extracellular vehicles EVs, as microvesicles, apoptotic bodies and  
73 exosomes (14). They are differentiated by specific membrane markers and size  
74 [microvesicles (100–1000 nm), exosomes (50–150 nm) and apoptotic bodies (50–  
75 2000 nm)]. EVs have been seen in blood, bile, urine bronchoalveolar lavage fluids  
76 (BALF), feces and saliva (15,16).

77 This study aimed at evaluation of the effectiveness of MSCS-MVs and MSCs against  
78 pulmonary toxicity induced by DENPs.

## 79 **Materials and Methods**

### 80 **Animals and groups**

81 Sixty male rats; albino species (80-120 days old and 220-250 g B.Wt) were  
82 obtained from in the animal house of faculty of Veterinary Medicine, Benha  
83 University. Seven days acclimatization period was allowed for rats. Animals  
84 were housed at constant temperature ( $22 \pm 2^{\circ}\text{C}$ ) and humidity (60%), with a  
85 12:12 hour light: dark cycle. They were given water ad libitum and standard  
86 pellet diet. All animals' procedures were performed in accordance with  
87 principles of Declaration of Helsinki (2008) and in accordance with the  
88 recommendations for the proper care and use of laboratory animals.  
89 Institutional animal ethical committee reviewed & approved our study  
90 according to the standard protocols of the Institutional Animal Care  
91 Committee.

92 Animals were randomly divided into the following groups:

93 **Group I (Control group, n=15)** divided into:

94 Subgroup 1A (n=8). Animals received intravenous injection of phosphate  
95 buffered saline (PBS) for 4 weeks.

96 Subgroup 1B (n=7): Received normal saline with 0.01% tween 80  
97 intratracheally as spray for 6 days intratracheally every two days.

98 **Group II (DENPs group, n=15).**

99 Animals treated with repeated doses of DENPs 180 µg/ rat for 6 days  
100 intratracheally every two day.

101 **Group III (MSCs group, n=15).**

102 Rats received a single dose of  $3 \times 10^6$  MSCs intravenously suspended in 0.5  
103 mL PBS after the last dose of DENPs.

104 **Group IV (MSCs-MVs group, n=15)**

105 Rats treated intravenously with a single dose of 0.5 mL (0.5 mg/mL) of MSCs-  
106 MVs after the last dose of DENPs.

107 In DENPs exposed rat groups, sodium pentobarbital was injected for  
108 anesthesia intraperitoneally (60 mg/kg b.wt). A 24-gauge cannula via the  
109 mouth was inserted into the trachea. DENPs suspensions and normal saline  
110 were intratracheally instilled using a sterile syringe. Administration was done  
111 on days 1, 3, and 5.

112 ***Collection of DENPs.***

113 Collection of DENPs were done by operating petrol engines and duty light  
114 multi-cylinder diesel at a speed of 1500 rpm, as method mentioned by **Durga**  
115 ***et al. (17).*** They were suspended in sterile normal saline (NaCl 0.9%)  
116 containing tween 80 (0.01%) to decrease aggregation, Normal saline with  
117 0.01% tween 80 was given to control group. The size of collected particles  
118 was less than 2.5µm. Morphological analysis and demonstration of the

119 presence of nano-size particles were examined by Transmission Electron  
120 Microscope (HR-TEM) (JEOL 3010).

### 121 ***MSCs Isolation and Ex Vivo Expansion.***

122 Ten to sixteen weeks old male rats were sacrificed by cervical dislocation.  
123 Bone marrow cells were obtained by flushing femurs and tibias with sterile  
124 PBS. After centrifugation, cells were resuspended in alpha-MEM  
125 supplemented with 10% selected fetal bovine serum and 80 ug/mL gentamicin  
126 and plated at a density of  $1 \times 10^6$  nucleated cells/cm<sup>2</sup>. Non-adherent cells were  
127 removed after 72 hours by media change. When foci reached confluence,  
128 adherent cells were detached with 0.25% trypsin, 2.65 mM EDTA, centrifuged  
129 and subcultured at 7.000 cells/cm<sup>2</sup>. After two subcultures, adherent cells were  
130 characterized and transplanted **(18)**.

### 131 ***Immunophenotyping of MSCs***

132 Immunophenotyping was performed by flowcytometry analysis after  
133 immunostaining with monoclonal antibodies against CD73 (FITC-conjugated)  
134 from BD Pharmingen, USA, and CD90 (PE-conjugated), (HPA005785  
135 Sigma-Aldrich, St. Louis, MO, USA) **(18)**.

### 136 ***MSCs Intravenous Administration***

137 A total of  $0.5 \times 10^6$  MSC were suspended in 0.2 mL of 5% BPS and were  
138 administered via the tail vein rat. Control animals received 0.2 mL of vehicle.

### 139 ***Isolation of MSC-derived Microvesicles***

140 Microvesicles were isolated from supernatant of first, second, and third  
141 passages of MSCs cultured in a-MEM deprived of FBS [AQ10]. After  
142 centrifugation at 2000 xg for 20 min to remove debris, cell-free supernatant  
143 was centrifuged at 100,000 xg (ultracentrifuge of Beckman Coulter Optima L

144 90 K[ $\text{AQ11}$ ]) for 1h at 4°C, washed in serum-free medium 199 containing  
145 HEPES 25 mM (Sigma, St Louis, Missouri, USA), and subjected in the same  
146 conditions to a second ultracentrifugation **(19)**. The protein content of  
147 microvesicles pellet was quantified by the Bradford method (Bio-Rad,  
148 Hercules, Cat. No. 5000205 California, USA).

#### 149 ***Identification and detection of MSC-derived Microvesicles***

150 Flow cytometry was done for identification of MSCs using specific stem cell  
151 markers CD90 (Becton Dickinson, FACS Calibur) and CD44 (Miltenyi Biotec,  
152 Bergisch Gladbach, German) (20) and detection of MSCs-MVs was done by  
153 using transmission electron microscope ((JEM-2100, Joel Inc.) at 80 kV) (21).  
154 For detection of homing of MSCs into pulmonary tissue in rats, cells were  
155 labeled with PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich, Egypt)  
156 then were injected into the tail vein, the lung tissue was examined with a  
157 fluorescence microscope to detect the cells stained with PKH26 dye to ensure  
158 homing in tissue.

#### 159 **Histological studies.**

160 At the end of the experiment, animals were anaesthetized by ether inhalation,  
161 sacrificed and the lung was exposed and excised. Lung biopsies were divided  
162 and fixed immediately in 10% neutral buffered formalin. Paraffin sections were  
163 prepared and stained with hematoxylin and eosin (H and E) to verify  
164 histological details, Orcein stain was used to assess elastic fibers **(22)**.

165 Immunohistochemical staining was carried for the detection of expression of  
166 NF- $\kappa$ B (Labvision, ThermoScientific, USA) rabbit polyclonal antibody, code  
167 no. RB-1638. The reaction is cytoplasmic and the positive control was the

168 prostate using avidin biotin complex technique and the sections were  
169 counterstained by haematoxylin to visualize the nuclei **(23)**.

170 ***Morphometric study.***

171 Measurement of alveolar wall thickness was done in H&E stained sectioned,  
172 measurement of mean area% of elastic fiber content was measured in the  
173 Orcien-stained sections at a magnification of  $\times 400$  for each specimen and  
174 measurement of the optical density of NF- $\kappa$ B immunoreactivity was done  
175 in 10 high-power fields using the binary mode. Measurement of alveolar  
176 thickness, pneumocytes count were quantified in 10 images for each group  
177 using Image-Pro Plus program version 6.0 (Media Cybernetics Inc., Bethesda,  
178 Maryland, USA). (computer system in the morphometric unit in the  
179 Histology Department, Faculty of Medicine, Cairo University).

180 ***Collection and analysis of bronchoalveolar lavage fluid (BALF)***

181 After scarification of all animals the trachea were canalized and the lungs  
182 were washed 3 times with 7.0 ml of normal sterile saline (NaCl 0.9%). There  
183 were no differences in volume of BALF collected from different groups. The  
184 collected BAL fluid was centrifuged for 15 min at 1500 rpm to precipitate the  
185 cells. The cells were then washed with buffer consisting of 0.58g Na<sub>2</sub>HPO<sub>4</sub>,  
186 4.03g NaCl, 0.1g KCl, 0.5g glucose and 0.1g KH<sub>2</sub>PO<sub>4</sub> in 500ml of distilled  
187 water and finally suspended at  $2 \times 10^5$  cells/ml in buffer. This was followed by  
188 staining with diff-quick (Belgium), fixation in methanol and observation under a  
189 light microscope. The concentration of macrophages, polymorphonuclear  
190 leukocytes (PMN), neutrophil, total cell count and total protein in BALF was  
191 analyzed according to the described protocols **(24)**. Total proteins and

192 albumin were assayed as an indicator of elevated permeability of capillary-  
193 broncho-alveolar barrier **(25)** and lactate dehydrogenase (LDH) estimation  
194 was assessed as an indicator of lung tissue injury **(26)**. Cytokines analysis of  
195 Interleukin-6 (IL-6) and tumor necrosis factor (TNF- $\alpha$ ) was also done in BALF.  
196 Total proteins of BAL fluid were quantified by Bradford reagent (BioRad,  
197 Hercules, Ca) as directed by the manufacturer's protocol. Lactate  
198 dehydrogenase (LDH) was assayed using colorimetric assay kit (Sigma-  
199 Aldrich, Merck, USA. Cat No. MAK066). Albumin (BCG) assay kit was  
200 obtained from Abcam (UK, Cat No. ab235628). ELISA kits were used for IL-6  
201 and TNF alpha assays (Abcam, UK, Cat No. ab100772 & Cat No. ab100785  
202 respectively). All assays were conducted as directed by the manufacturer's  
203 protocols.

## 204 **Statistical analysis**

205 Data was analyzed using SPSS computer program version 22.0. Quantitative  
206 data was expressed as means  $\pm$  standard deviation, median and range.  
207 Qualitative data was expressed as number and percentage. The data were  
208 tested for normality using Shapiro-Wilk test. The nonparametric Mann-  
209 Whitney test and Kruskal-Wallis test were used for data which wasn't  
210 normally distributed. Independent Samples t-test and One-way analysis of  
211 variance test were used for normally distributed data. Chi-Square test was  
212 used for comparison between qualitative variables. A 5% level was chosen as  
213 a level of significance in all statistical tests used in the study.

## 214 **Results**

### 215 ***Histological results.***



216 ***Characterization and homing of MSCs and MSCs-MVs.***

217 MSCs were recognized at 14-day culture by inverted microscope as adherent  
218 spindle-shaped cells with some polyhedral cells in between (**Fig. 1A**). MSCs  
219 labelled with PKH26 fluorescent dye were identified in vitro by means of a  
220 fluorescent microscope (**Fig. 1B**). MSCs labelled with PKH26 fluorescent dye  
221 were recognized in lung by their strong red fluorescence using fluorescent  
222 microscope (**Fig. 1C**). TEM of MSCs-MVs showed spheroids appearance with  
223 diameter less than 100 nm (**Fig. 1D**). Flow cytometry revealed that there were  
224 positive CD90 and CD44 as surface marker of MSCs.

225 ***Hematoxylin and eosin results (H&E).***

226 Examination of lung sections of control rats (group I) showed a normal lung  
227 structure with bronchioles and blood vessels in between lung alveoli that has  
228 thin inter alveolar septa (**Fig. 2 a, 2b**). The lung alveoli of group II (DENPs  
229 treated group) showed thick interalveolar septa with inflammatory cellular  
230 infiltration around alveoli and bronchiole, extravasated red blood cells (RBCs)  
231 and desquamated epithelial cells in the lumen of the bronchiole (**Fig. 2c, 2d**)  
232 In group III (MSCs treated) lung sections revealed bronchioles, alveoli with  
233 thin interalveolar septa. Few cellular infiltrations and less extravasated RBCs  
234 were detected (**Fig. 2e, 2f**). Lung sections in group IV (MSCs-MVs) showed  
235 many alveoli of variable size with alveolar ducts and thin interalveolar septa  
236 as in control group with few others showed thickened interalveolar septa with  
237 few mononuclear cellular infiltration (**Fig. 2g**).

238 ***Orcein stain results.***

239 Group I sections showed continuous dark reddish-brown elastic fibers around  
240 the bronchiole, walls of the alveoli and wall of blood vessels (**Fig. 3a**).  
241 Sections of group II showed minimal accumulation of reddish-brown elastic  
242 fibers around the bronchiole, walls of the alveoli, and wall of dilated congested  
243 blood vessel (**Fig. 3b**). Group III (MSCs group) lung tissue showed moderate  
244 accumulation of reddish-brown elastic fibers around the bronchiole, wall of  
245 congested blood vessel, and walls of the alveoli (**Fig. 3c**). Group IV (MSCs-  
246 MVs) lung showed marked accumulation of reddish-brown elastic fibers in the  
247 bronchiole, wall of congested blood vessel and walls of the alveoli (**Fig. 3d**).

#### 248 ***Immunohistochemical results***

249 NF- $\kappa$ B immunoreactivity in the control groups, cytoplasmic immunoreactivity  
250 was found in some alveoli (Fig 4A). In the DENPs group, increased  
251 cytoplasmic immunoreactivity was observed in multiple alveolar cells (Fig.  
252 4B), whereas the (MSCs group) and (MCSs-MVS group) showed decreased  
253 cytoplasmic immunoreactivity in alveoli compared with the DENPs group  
254 (Figs. 4C and D).

#### 255 ***Morphometric results:***

##### 256 ***The alveolar septal wall thickness.***

257 Group II (DENPs group) showed significant increase in the alveolar thickness  
258 ( $p < 0.001$ ) in comparison to control. While the alveolar thickness in Group III  
259 (MSCs group) and in Group IV (MSCs-MVs group) exhibited significant  
260 decrease ( $p < 0.05$ ) (**Table 1**).

##### 261 ***Mean area percentage of elastic fibers.***

262 There was a significant difference in the mean area percentages of elastic  
 263 fibers in DENPs group as compared with control group ( $p > 0.05$ ) and a  
 264 significant increase in elastic fibers in both MSCs and MSCs-MVs treated  
 265 groups in comparison to DENPs group ( $p < 0.05$ ) (table 1).

266 **Optical density of NF- $\kappa$ B**


267 There was a significant increase ( $P < 0.05$ ) in the mean optical density of NF-  
 268  $\kappa$ B immunoreactivity in the DENPs group compared with the other groups  
 269 (table 1).

270 **Table 1. Alveolar wall thickness ( $\mu$ m), mean area percentage of elastic fibers**  
 271 **and optical density of NF- $\kappa$ B.**

Groups	Control group	DENPs group	MSCs group	MSCs-MVs group
Alveolar wall thickness ( $\mu$ m)	2.61 ± 1.51	11.26 ± 9.12 *	5.32 ± 1.70 <sup>a*</sup>	3.13 ± 0.42 <sup>a</sup>
Mean area percentage of elastic fibers	9.94 ± 0.83	1.42 ± .03 *	6.29 ± 0.10 <sup>a*</sup>	7.98 ± 0.90 <sup>a</sup>
Optical density of NF- $\kappa$ B	0.1 ± 0.01	3.37 ± 0.02	0.19 ± 0.03 <sup>a*</sup>	0.12 ± 0.07 <sup>a</sup>

272  
 273 **Note:** \* as compared with control normal group, <sup>a</sup> as compared with DENPs  
 274 treated group. \* $P \leq 0.05$ , significant difference

275



276  
277  
278  
279

**Cytokine analysis, inflammatory cells and total proteins in BALF.**

280  
281  
282  
283  
284  
285  
286  
287

In Group II (DENPs group), the levels of TNFα and IL-6 were significantly increased in BALF. However, IL-6 and TNFα levels in MSCs and in MSCs-MVs treated groups were significantly decreased when compared to DENPs toxicity group. In DENPs group there was a significant elevation in macrophages, whereas PMN and neutrophil levels were increased. On the other hand, MSCs and MSCs-MVs treated groups exhibited significant decrease in macrophages, PMN and neutrophil levels when compared with DENPs group (Table 2).

288  
289  
290  
291  
292  
293

The total protein was increased in DENPs group. MSCs and MSCs-MVs treated groups showed significant decrease when compared to the DENPs group. Albumin concentration was elevated in DENPs toxicity group and significantly decreased in both MSCs and MSCs-MVs treated groups. Whereas, the LDH level was increased in DENPs group and decreased in both MSCs and MSCs-MVs treated groups (Table 2).

294  
295


**Table 2. Levels of TNF-α, IL-6, inflammatory cells, total cell count and total proteins in BALF.**

Groups	Control group	DENPs group	MSCs group	MSCs-MVs group
IL-6 (pg/ml)	0.98 ± 0.12	3.92± 0.34 *	1.39± 0.60a <sup>a*</sup>	1.03± 0.15 <sup>a</sup>
TNF-α (pg/ml)	25.89± 6.59	63.44± 10.53 *	29.34± 0.20 <sup>a</sup>	28.78± 0.90 <sup>a</sup>
Macrophages	0.98 ± 0.12	2.92± 0.34 *	1.21± 0.15 <sup>a</sup>	1.00± 0.91 <sup>a</sup>
PMNs	25.89± 6.59	82.41± 10.53 *	29.34± 0.20 <sup>a</sup>	27.78± 0.90 <sup>a</sup>
Neutrophils	40.31 ± 1.94	63.44± 10.53 *	49.32± 2.14 <sup>a*</sup>	47.58± 0.32 <sup>a*</sup>
Total proteins (mg)	57.41 ± 1.46	120.34± 4.20 *	61.33± 8.70 <sup>a*</sup>	59.08± 0.81 <sup>a</sup>
Albumin (mg)	2.1± 0.65	4.9± 2.73 *	2.1± 0.10 <sup>a</sup>	2.0± 0.11 <sup>a</sup>
LDH	2.01± 1.49	0.95± 0.83 *	1.7± 0.50 <sup>a</sup>	1.8± 0.81 <sup>a</sup>

296

297 **Note:** \* as compared with control normal group, <sup>a</sup> as compared with DENPs  
 298 treated group. \*P≤0.05, significant difference.

299



300

301

## 302 **Discussion**

303 Since 1990 it was realized that the adverse health effects of DENPs depend mainly  
304 on pulmonary inhalation with subsequent induction of oxidative stress, pro-  
305 inflammatory signaling molecules and genotoxicity. DENPs are translocated across  
306 the airway respiratory epithelia and enter the circulatory system, along with locally  
307 produced inflammatory signaling molecules and oxidizing molecules which initiate  
308 systemic inflammation, oxidative stress and systemic distribution of genotoxins **(2)**.  
309 These facts confirm our findings of elevated levels of inflammatory cytokines; IL-6  
310 and TNF-  $\alpha$  as well as inflammatory cellular infiltration of the lung tissue in DENPs  
311 exposed rat group. More recently, **Durga et al. (27)** stated that inflammatory  
312 cytokines, reactive oxygen species (ROS) and genotoxins induce endothelial cells  
313 transition into mesenchymal fibroblast-like cells with subsequent progression of  
314 chronic diseases to organ fibrosis and carcinogenesis. It was shown that endothelial  
315 protein pattern changes with modulation of the expressions of endothelial/ fibrotic  
316 markers and extracellular matrix proteins. These observations could explain findings  
317 of this study that revealed significant accumulation of elastic fibers around the  
318 bronchiole, walls of the alveoli, and wall of the congested blood vessel together with  
319 marked increase in the alveolar wall thickness in lung tissues of DENPs exposed rat  
320 group. These findings could also be attributed to activation of immune cells by  
321 reactive oxygen species (ROS) and reactive nitrogen species (RNS) which initiate  
322 pulmonary fibrosis as proved in the previous study conducted by **Yetuk et al. (28)**.  
323 One of the key inducers of inflammatory responses is NFK-B (26). Activation of NFK-  
324 B results from interactions between polyaromatic hydrocarbons found in DENPs with  
325 the intracellular Aryl-hydrocarbon receptors **(29, 30)**. Also, increase of nuclear factor  
326 kappa B by diesel exhaust particles in mouse epidermal cells through

327 phosphatidylinositol 3-kinase/Akt signaling pathway (29). Evidence of Lung injury in  
328 our study was shown by elevated albumin level in BALF. These findings coincided  
329 with previous studies (31,32).

330 As regards use of MSCs and MSCs-MVs, results of this study showed that both  
331 treated rat groups showed significant amelioration of the histological picture of lung  
332 tissue injury, significant decrease in inflammatory cytokines; IL-6 and TNF- $\alpha$  and  
333 significant decrease in albumin and increase in LDH levels in BALF. These  
334 observations could be attributed to the anti-inflammatory and immunomodulatory  
335 capacity of MSCs (5, 9). Willis et al. (33) reported that MSCs-derived EVs; one type  
336 of extracellular vesicles significantly blunt inflammation, decrease fibrosis, and  
337 improve pulmonary functions in experimental bronchopulmonary dysplasia. MSCs-  
338 MV mechanism of action involves suppression of the pro-inflammatory state and  
339 switch to an anti-inflammatory state via modulation of macrophage functions in lung  
340 tissues. These facts could explain our findings of decreased markers of lung injury  
341 which treated by MSCs-MS; albumin as well as decreased inflammatory cytokines,  
342 inflammatory cells infiltration of the lung and increase LDH with subsequent increase  
343 in elastic fibers and decrease in alveolar wall thickness.

344 MSC-MVs have many therapeutic effects in different diseases, as renal injury, brain  
345 injury, heart injury and lung injury (34). The therapeutic ability of MSC-MVs has been  
346 studied in different disease models, showing a similar or even superior effect to  
347 MSCs themselves (35-36) which has showed in our result.

348 Recent studies on MSC-MVs in preclinical experimental models of inflammatory lung  
349 diseases have shown that they could be safely and easily used in lung disease  
350 therapies (37).

351 In Conclusion, MSCs-MVs and MSCs showed significant protective effects against  
352 DENPs damaging effects on the lung tissues via their regenerative capacity and anti-  
353 inflammatory effects.

## 354 REFERENCES

- 355  
356 1. Khalek IA, Bougher TL, Merritt PM, Zielinska B. Regulated and unregulated  
357 emissions from highway heavy-duty diesel engines complying with U.S.  
358 Environmental Protection Agency 2007 emissions standards. *J Air Waste*  
359 *Manag Assoc.* 2011 Apr; 61(4):427-42. [[PubMed](#)] [[Ref list](#)] PMID: 21516938  
360
- 361 2. Steiner S, Bisig C, Petri-Fink A, Rothen-Rutishauser B. Diesel exhaust: current  
362 knowledge of adverse effects and underlying cellular mechanisms. *Arch Toxicol.*  
363 2016; 90(7): 1541–1553. doi: 10.1007/s00204-016-1736-5 PMID: 27165416  
364
- 365 3. Abderrahim Nemmar, Priya Yuvaraju, Sumaya Beegam, Mohamed A.  
366 Fahim, Badreldin H. Ali. Cerium Oxide Nanoparticles in Lung Acutely Induce  
367 Oxidative Stress, Inflammation, and DNA Damage in Various Organs of Mice.  
368 *Oxid Med Cell Longev.* 2017; 9639035. doi: 10.1155/2017/9639035  
369 PMID: PMC5368370. PMID: 28392888  
370
- 371 4. Samantha J. Snow, John McGee, Desinia B. Miller, Virginia Bass, Mette C.  
372 Schladweiler, Ronald F. Thomas, Todd Krantz, Charly King, Allen D. Ledbetter,  
373 Judy Richards, Jason P. Weinstein, Teri Conner, Robert Willis, William P. Linak,  
374 David Nash, Charles E. Wood, Susan A. Elmore, James P. Morrison, Crystal L.  
375 Johnson, Matthew Ian Gilmour, Urmila P. Kodavanti. Inhaled diesel emissions  
376 generated with cerium oxide nanoparticle fuel additive induce adverse  
377 pulmonary and systemic effects. *Toxicol Sci.* 2014 Dec; 142(2): 403–  
378 417. doi: 10.1093/toxsci/kfu187  
379
- 380 5. Abdelmawgoud H, Saleh A. Anti-inflammatory and antioxidant effects of  
381 mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model.  
382 *Adv Clin Exp Med.* 2018 Jul;27(7):873-880. doi: 10.17219/acem/73720.  
383
- 384 6. Shi H, Liang M, Chen W, Sun X, Wang X, Li C, Yang Y, Yang Z, Zeng W.  
385 Human induced pluripotent stem cell-derived mesenchymal stem cells alleviate  
386 atherosclerosis by modulating inflammatory responses. *Mol Med Rep.* 2018;  
387 17(1):1461-1468. doi: 10.3892/mmr.2017.8075.  
388
- 389 7. Mao F, Tu Q, Wang L, Chu F, Li X, Li HS, Xu W. Mesenchymal stem cells and  
390 their therapeutic applications in inflammatory bowel disease. *Oncotarget.* 2017;  
391 8(23):38008-38021. doi: 10.18632/oncotarget.16682.  
392
- 393 8. Shin TH, Kim HS, Choi SW, Kang KS. Mesenchymal Stem Cell Therapy  
394 for Inflammatory Skin Diseases: Clinical Potential and Mode of Action. *Int J Mol*  
395 *Sci.* 2017 Jan 25;18(2). pii: E244. doi: 10.3390/ijms18020244.  
396




- 397 9. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S.  
398 Mesenchymal stem cell transplantation reverses multiorgan dysfunction in  
399 systemic lupus erythematosus mice and humans. *Stem Cells*. 2009; 27:1421–  
400 1432. doi: [10.1002/stem.68](https://doi.org/10.1002/stem.68).
- 401
- 402 10. Robert Y.L. Tsai. Balancing Self-Renewal against Genome Preservation in  
403 Stem Cells: How to Have the Cake and Eat It Too? *Cell Mol Life Sci*. 2016;  
404 73(9): 1803–1823. doi: [10.1007/s00018-016-2152-y](https://doi.org/10.1007/s00018-016-2152-y) PMID: [PMC5040593](https://pubmed.ncbi.nlm.nih.gov/27040593/)
- 405
- 406 11. Nagaria P, Robert C, Rassool FV. DNA double-strand break response in stem  
407 cells: mechanisms to maintain genomic integrity. *Biochim Biophys*  
408 *Acta*. 2013;1830(2):2345–2353. doi: [10.1016/j.bbagen.2012.09.001](https://doi.org/10.1016/j.bbagen.2012.09.001).
- 409
- 410 12. Mandal PK, Blanpain C, Rossi DJ. DNA damage response in adult stem cells:  
411 pathways and consequences. *Nat Rev Mol Cell Biol*. 2011;12(3):198–202. doi:  
412 [10.1038/nrm3060](https://doi.org/10.1038/nrm3060).
- 413
- 414 13. Kowalska M, Wegierek-Ciuk A, Brzoska K, Wojewodzka M, Meczynska-  
415 Wielgosz S, Gromadzka-Ostrowska J, Mruk R, Øvrevik J, Kruszewski  
416 M, Lankoff A. Genotoxic potential of diesel exhaust particles from the  
417 combustion of first- and second-generation biodiesel fuels—the FuelHealth  
418 project. *Environ Sci Pollut Res Int*. 2017; 24(31): 24223–24234.  
419 doi: [10.1007/s11356-017-9995-0](https://doi.org/10.1007/s11356-017-9995-0)
- 420 14. Fujita, Y.; Yoshioka, Y.; Ochiya, T. Extracellular vesicle transfer of cancer  
421 pathogenic components. *Cancer Sci*. 2016, 107, 385–390. [CrossRef] [PubMed]
- 422 15. Witwer, K.W.; Buzas, E.I.; Bemis, L.T.; Bora, A.; Lasser, C.; Lotvall, J.; Nolte-  
423 Hoen, E.N.; Piper, M.G.; Sivaraman, S.; Skog, J.; et al. Standardization of  
424 sample collection, isolation and analysis methods in extracellular vesicle  
425 research. *J. Extracell. Vesicles* 2013, 2, 20360. [CrossRef] [PubMed]
- 426 16. Yanez-Mo, M.; Siljander, P.R.; Andreu, Z.; Zavec, A.B.; Borrás, F.E.; Buzas,  
427 E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties  
428 of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles*  
429 2015, 4, 27066. [CrossRef] [PubMed]
- 430
- 431 17. Durga M, Nathiya S, Devasena T. Protective role of fenugreek leaf extract and  
432 Quercetin against petrol exhaust nanoparticle induced lipid peroxidation and  
433 oxidative stress in rat erythrocytes *in vitro*. *Asian J Pharm Clin Res* 2015;8(1):  
434 237-241.  
435 [http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.852.8353&rep=rep1&](http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.852.8353&rep=rep1&type=pdf)  
436 [type=pdf](http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.852.8353&rep=rep1&type=pdf)
- 437
- 438 18. Baghaei K, Hashemi SM, Tokhanbigli S, Asadi Rad A, Assadzadeh-Aghdaei  
439 H, Sharifian A, Zali MR. Isolation, differentiation, and characterization of  
440 mesenchymal stem cells from human bone marrow. *Gastroenterol Hepatol Bed*  
441 *Bench*. 2017 Summer;10(3):208-213. PMID: [PMC5660271](https://pubmed.ncbi.nlm.nih.gov/27040271/).
- 442
- 443 19. Gorgun C, Reverberi D, Rotta G, Villa F, Quarto R, Tasso R. Isolation and Flow  
444 Cytometry Characterization of Extracellular-Vesicle Subpopulations Derived  
445 from Human Mesenchymal Stromal Cells. *Curr Protoc Stem Cell Biol*  
446 2019;48:e76.(PMID: 30624011) doi: [10.1002/cpsc.76](https://doi.org/10.1002/cpsc.76)

447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496


20. Nassar W, El-Ansary M, Sabry D, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. *Biomater Res* 2016;20:21. (PMCID: PMC4974791) doi: [10.1186/s40824-016-0068-0](https://doi.org/10.1186/s40824-016-0068-0)
21. Faruk EM, El-desoky RE, Al-Shazly AM, Taha NM. Does Exosomes Derived Bone Marrow Mesenchymal Stem Cells Restore Ovarian Function by Promoting Stem Cell Survival on Experimentally Induced Polycystic Ovary in Adult Female Albino Rats? (Histological and Immunohistochemical Study). *Stem Cell Res Ther* 2018;8:442. doi: [10.4172/2157-7633.1000442](https://doi.org/10.4172/2157-7633.1000442)
22. Alturkistani HA, Tashkandi FM, Mohammedsaleh ZM. Histological Stains: A Literature Review and Case Study. *Glob J Health Sci.* 2016; 8(3): 72–79. doi: [10.5539/gjhs.v8n3p72](https://doi.org/10.5539/gjhs.v8n3p72)
23. Bancroft JD, Layton C. The Hematoxylin and eosin. In: Suvarna S. K, Layton C, Bancroft J. D, editors. *Theory Practice of histological techniques*. 7th ed. Ch. 10 and 11. Philadelphia: Churchill Livingstone of El Sevier; 2013. pp. 179–220. <http://dx.doi.org/10.1016/b978-0-7020-4226-3.00010-x>
24. Collins AM, Rylance J, Wootton DG, Wright AD, Wright AK, Fullerton DG, Gordon SB. Bronchoalveolar lavage (BAL) for research; obtaining adequate sample yield. *J Vis Exp.* 2014 Mar 24;(85). doi: [10.3791/4345](https://doi.org/10.3791/4345).
25. Oyabu T, Myojo T, Lee BW, Okada T, Izumi H, Yoshiura Y, Tomonaga T, Li YS, Kawai K, Shimada M, Kubo M, Yamamoto K, Kawaguchi K, Sasaki T, Morimoto Y. Biopersistence of NiO and TiO<sub>2</sub> nanoparticles following intratracheal instillation and inhalation. *Int J Mol Sci.* 2017; 18(12): 2757. doi: [10.3390/ijms18122757](https://doi.org/10.3390/ijms18122757).
26. Carolina Vieirade Souza, Sergio MachadoCorrêa. Polycyclic aromatic hydrocarbons in diesel emission, diesel fuel and lubricant oil. *Fuel* 2016; 185: 925 – 931. <https://doi.org/10.1016/j.fuel.2016.08.054>.
27. Durga M, Nathiya S, Rajasekar A, Devasena T. Effects of ultrafine petrol exhaust particles on cytotoxicity, oxidative stress generation, DNA damage and inflammation in human A549 lung cells and murine RAW 264.7 macrophages. *Environ Toxicol Pharmacol* 2014;38(2):518-30.
28. Yetuk G, Pandir D, Bas H. Protective role of catechin and quercetin in sodium benzoate-induced lipid peroxidation and the antioxidant system in human erythrocytes in vitro. *ScientificWorldJournal* 2014;2014:874824.
29. Jennifer A. Bartlett,<sup>1</sup> Matthew E. Albertolle,<sup>2</sup> Christine Wohlford-Lenane,<sup>1</sup> Alejandro A. Pezzulo,<sup>3</sup> Joseph Zabner,<sup>3</sup> Richard K. Niles,<sup>2</sup> Susan J. Fisher,<sup>2</sup> Paul B. McCray, Jr.,<sup>1</sup> and Katherine E. Williams: Protein composition of bronchoalveolar lavage fluid and airway surface liquid from newborn pigs. *Am J Physiol Lung Cell Mol Physiol.* 2013; 305(3): L256–L266. doi: [10.1152/ajplung.00056.2013](https://doi.org/10.1152/ajplung.00056.2013).
30. Samantha J S, John M, Desinia B, Virginia B, Mette C et al. Inhaled Diesel Emissions Generated with Cerium Oxide Nanoparticle Fuel Additive Induce Adverse Pulmonary and Systemic Effects. *Toxicological sciences*, 2014, 142., 2
31. Pérez L, Muñoz-Durango N, Riedel CA, Echeverría C, Kalergis AM, Cabello-Verrugio C, Simon F. Endothelial-to-mesenchymal transition: Cytokine-mediated

- 497 pathways that determine endothelial fibrosis under inflammatory conditions.  
498 **Cytokine Growth Factor Rev.** 2017 Feb;33:41-54. doi:  
499 [10.1016/j.cytogfr.2016.09.002](https://doi.org/10.1016/j.cytogfr.2016.09.002).
- 500 32. Ma JY, Mercer RR, Barger M, Schwegler-Berry D, Scabilloni J, Ma  
501 JK, Castranova V. Induction of pulmonary fibrosis by cerium oxide  
502 nanoparticles. *Toxicol Appl Pharmacol.* 2012; 262(3):255-64. doi:  
503 [10.1016/j.taap.2012.05.005](https://doi.org/10.1016/j.taap.2012.05.005).
- 504 33. Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson  
505 M, Kwong A, Mitsialis SA, Kourembanas S. Mesenchymal stromal cell  
506 ameliorates experimental bronchopulmonary dysplasia and restore lung function  
507 through macrophage immunomodulation. *Am J Respir Crit Care Med.* 2018;  
508 197(1):104-116. doi: [10.1164/rccm.201705-0925OC](https://doi.org/10.1164/rccm.201705-0925OC).
- 509 34. Phinney, D.G.; Pittenger, M.F. Concise Review: MSC-Derived Exosomes for  
510 Cell-Free Therapy. *Stem Cells* 2017, 35, 851–858. [CrossRef] [PubMed]
- 511 35. Bian, S.; Zhang, L.; Duan, L.; Wang, X.; Min, Y.; Yu, H. Extracellular vesicles  
512 derived from human bone marrow mesenchymal stem cells promote  
513 angiogenesis in a rat myocardial infarction model. *J. Mol. Med. (Berl.)* 2014, 92,  
514 387–397. [CrossRef] [PubMed]
- 515 36. Faruk EM, El Mansy A, Alasmari WAM, Elshazly AME. The possible protective  
516 role of quercetin on induced cardiac Oxidative DNA Damage by repeated  
517 exposure to diesel exhaust nanoparticles in rats (a histological and  
518 immunohistochemical study). *J Histochem Histopathol* 2018;5(2). doi: [10.7243/2055-091X-5-2](https://doi.org/10.7243/2055-091X-5-2).
- 519 37. Rezaie Z, Ardeshiryajimi A, Ashkezari MD, Seifati SM. Antitumoral potential of  
520 microvesicles extracted from human adipose-derived mesenchymal stem cells  
521 on human breast cancer cells. *J Can Res Ther* 2019,2,234-238. Available  
522 from: <http://www.cancerjournal.net/preprintarticle.asp?id=251396>  
523  
524  
525

## 526 **Figure Legends**





527





528  
529  
530  
531  
532  
533  
534  
535  
536

**E.**



**Fig 1.** (A) Inverted microscope micrograph of a culture of bone marrow-derived mesenchymal stem cells on day 14 of isolation and culture. The attached cells form colonies. These cells are spindle shaped (↑) with some polyhedral cells (\*) in between the colonies (X1000). (B) A fluorescent microscope photograph showing MSCs labelled with PKH26 fluorescent dye in vitro (arrows) (λ~ 1000); (C) A fluorescent microscope photograph showing MSCs labelled with PKH26 fluorescent dye in lung (arrows) (λ~ 1000). (D) Electron micrograph of micro vesicles showing spheroid appearance (black arrows) in lung (100 nm). (E) flow cytometry which revealed that MSCs were have CD90+ and CD44.




537  
538  
539



540  
541





542  
543  
544



545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560

**Fig 2.** (a) A photomicrograph of a section in rat lung of group I (control group) showing alveoli (A), alveolar duct (AD), bronchiole (B) thin interalveolar septa (arrows) and a blood vessel (V) H&E, 200. (b) A section in rat lung of group I (control group) showing pneumocyte type I (arrows), pneumocyte type II (lines) and alveolar macrophages (star), H&E, 400. (c) Lung tissue of group II (DENPs treated group) showed some collapsed alveoli (c) with thick interalveolar septa (T), cellular infiltration around bronchiole and alveoli (stars), extravasated red blood cells (b) and exfoliated epithelial cells in the lumen of bronchiole (f). (d) Group III (MSCs group) showed apparently thin interalveolar septa (arrows) with some dilated ruptured alveoli (RA) and cellular infiltration (stars) H&E, 200. (e) Sections of group III (MSCs group) showed some alveoli normal (AL) with thin interalveolar septa (arrows) and few cellular infiltrations (stars) and less extravasated RBCs (b), others collapsed alveoli (CA) with thick interalveolar septa (T) H&E, 200. (f) Group IV (MSCs-EVs) showed many alveoli of variable size (A) with alveolar ducts (AD) and thin interalveolar septa (arrows) with few others showed thickened interalveolar septa (T) with few mononuclear cellular infiltration(stars).




561

A


B)

B



562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574

Fig 3. (A) A photomicrograph of Group I (control group) showing continuous reddish-brown elastic fibers (arrows) around the walls of the alveoli (A), bronchiole (B) and blood vessel (bv) (Orcein stain, X200). (B) Group II showing mild accumulation of reddish-brown elastic fibers (arrows) around the bronchiole (B), walls of the alveoli (A) and wall of dilated blood vessel (V) (Orcein stain, X200). (C) Group III (MSCs group) showing moderate accumulation of reddish-brown elastic fibers (arrows) around the bronchiole (B), wall of congested blood vessel (bv) and walls of the alveoli (A) (Orcein stain, X200). (D) Group IV (MSCs-MVs) showing marked amount of reddish-brown elastic fibers around the bronchiole passages (B) and walls of the alveoli (A) (Orcein stain, X200).



575  
576  
577

Fig 4. (A) Photomicrograph of lung section of Group I showed negative NF- $\kappa$ B immunoreactivity (arrow) within the cytoplasm of cells. (B) Group II (DENPs treated group) rat lung showing marked positive NF- $\kappa$ B immunoreactivity (arrows). (C) group III (MSCs group) showing moderate positive NF- $\kappa$ B immunoreactivity (arrows). (D) Group IV (MSCs-MVs) showing mild positive NF- $\kappa$ B immunoreactivity (arrows). (Immunostaining for NF- $\kappa$ B X200).

583  
584  
585

UNDER PEER REVIEW